Iovance Biotherapeutics Announces Regulatory And Clinical Updates For Lifileucel In Melanoma; Co. Reports ‘Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission’
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has provided feedback
All The Stocks That Moved Wednesday From CNBC’s ‘Fast Money: Halftime Report’
UPDATE: Thursday's edition of the CNBC summary has been published. Click here to see the calls from today.
CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors.
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Recap: Iovance Biotherapeutics Q4 Earnings
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
